Drug Trial Radar · NCT06520345
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
520
Planned (sponsor's estimate)
Start
Jul 26, 2024
Primary completion
Dec 2027
Study completion Dec 2030
Sponsor
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jul 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
177Lu-TLX591Drug
Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart
EnzalutamideDrug
Enzalutamide (starting dose 160 mg daily)
AbirateroneDrug
Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (up to 10 mg per day for the standard formulation)
DocetaxelDrug
Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone 5mg twice a day (or equivalent) for up to 10 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression-free SurvivalTime frame: 337days
Locations
33 sites in 6 countries. Site status is shown where the registry gives one.
Chao Family Comprehensive Cancer Centre
Orange, California · Active not recruiting
Biogenix Molecular LLC
Miami, Florida · Active not recruiting
United Theranostics
Glen Burnie, Maryland · Active not recruiting
XCancer Omaha
Omaha, Nebraska · Active not recruiting
Columbia University Herbert Irving Comphrensive Cancer Center
New York, New York · Recruiting
University Hospital
Cleveland, Ohio · Active not recruiting
OHSU Knight Cancer Center
Portland, Oregon · Active not recruiting
Intermountain Health
Murray, Utah · Active not recruiting
Intermountain Health
Salt Lake City, Utah · Active not recruiting
Mater Health Services Pty Ltd
Brisbane, Australia · Not yet recruiting
GenesisCare Maitland
East Maitland, Australia · Recruiting
Austin Health
Heidelberg, Australia · Recruiting
GensisCare Cabrini
Malvern, Australia · Recruiting
GenesisCare North Adelaide
North Adelaide, Australia · Recruiting
Royal North Shore Hospital
Saint Leonards, Australia · Recruiting
GenesisCare Tugun
Tugun, Australia · Recruiting
Westmead Hospital
Sydney, New South Wales, Australia · Recruiting
Nepean Hospital
Sydney, New South Wales, Australia · Recruiting
Wollongong Hospital
Wollongong, New South Wales, Australia · Recruiting
Australian Prostate Centre
Melbourne, Victoria, Australia · Recruiting
GenesisCare Murdoch
Perth, Western Australia, Australia · Recruiting
INITIO Medical Group
Burnaby, Canada · Recruiting
Sunnybrook Research Institute
Toronto, Canada · Recruiting
New Zealand Clinical Research - Christchurch
Christchurch, New Zealand · Recruiting
Auckland City Hospital
Grafton, Auckland, New Zealand · Recruiting
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye) · Not yet recruiting
Ankara University Cebeci Hospital
Ankara, Turkey (Türkiye) · Recruiting
Hacettepe University Medical Faculty
Ankara, Turkey (Türkiye) · Recruiting
Maslak Acibadem Hospital
Istanbul, Turkey (Türkiye) · Recruiting
Charing Cross Hospital
London, United Kingdom · Recruiting
Royal Free Hospital
London, United Kingdom · Not yet recruiting
University College London Hospitals
London, United Kingdom · Recruiting
Genesiscare Windsor
Windsor, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.